Qicai Li1, Shirong Song1,2, Guangzhen Ni2, Yu Li1, Xiaohui Wang1,3. 1. Department of Traumatology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. 2. Department of Clinical Laboratory, People's Hospital of Weifang, Weifang, Shandong, China. 3. Department of Traumatology, The Central Hospital of Linyi, Linyi, Yishui, Shandong, China.
Abstract
OBJECTIVE: Emerging evidence has suggested that circulating microRNAs (miRNAs) in body fluids have novel diagnostic and prognostic significance for patients with malignant diseases. The lack of useful biomarkers is a crucial problem of osteosarcoma (OS); Previous study has reported that miR-542-3p was significantly upregulated in osteosarcoma tissues and miR-542-3p may be as an oncogene in osteosarcoma pathogenesis. In our study, we investigated the circulating miR-542-3p and its clinical relevance in osteosarcoma. METHODS: Serum MiR-542-3p levels were determined by quantitative real-time PCR assays (qRT-PCR) in 76 patients with OS and 76 healthy volunteers. Patient survival analyses were performed by Kaplan-Meier analyses and Cox regression models. All statistical tests were two-sided. RESULTS: It was observed that the serum levels of miR-542-3p was significantly higher in patients with OS compared with the control groups (P< 0.01). High serum of miR-542-3p was significantly associated with advanced tumor stage and shorter survival (P< 0.01). ROC curve analysis calculated the ideal miR-542-3p cut-off value of 0.84 in prediction of OS, with a sensitivity of 53.8%, specificity of 93.6%, positive predictive value of 87.3% and negative predictive value of 63.7%. CONCLUSIONS: The results showed that serum miR-542-3p levels could serve as a non-invasive blood biomarker for tumor monitoring and prognostic prediction in osteosarcoma patients.
OBJECTIVE: Emerging evidence has suggested that circulating microRNAs (miRNAs) in body fluids have novel diagnostic and prognostic significance for patients with malignant diseases. The lack of useful biomarkers is a crucial problem of osteosarcoma (OS); Previous study has reported that miR-542-3p was significantly upregulated in osteosarcoma tissues and miR-542-3p may be as an oncogene in osteosarcoma pathogenesis. In our study, we investigated the circulating miR-542-3p and its clinical relevance in osteosarcoma. METHODS: Serum MiR-542-3p levels were determined by quantitative real-time PCR assays (qRT-PCR) in 76 patients with OS and 76 healthy volunteers. Patient survival analyses were performed by Kaplan-Meier analyses and Cox regression models. All statistical tests were two-sided. RESULTS: It was observed that the serum levels of miR-542-3p was significantly higher in patients with OS compared with the control groups (P< 0.01). High serum of miR-542-3p was significantly associated with advanced tumor stage and shorter survival (P< 0.01). ROC curve analysis calculated the ideal miR-542-3p cut-off value of 0.84 in prediction of OS, with a sensitivity of 53.8%, specificity of 93.6%, positive predictive value of 87.3% and negative predictive value of 63.7%. CONCLUSIONS: The results showed that serum miR-542-3p levels could serve as a non-invasive blood biomarker for tumor monitoring and prognostic prediction in osteosarcomapatients.
Authors: G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco Journal: Clin Transl Oncol Date: 2019-04-04 Impact factor: 3.405
Authors: Hanna Kosela-Paterczyk; Agnieszka Paziewska; Maria Kulecka; Aneta Balabas; Anna Kluska; Michalina Dabrowska; Magdalena Piatkowska; Natalia Zeber-Lubecka; Filip Ambrozkiewicz; Jakub Karczmarski; Michal Mikula; Piotr Rutkowski; Jerzy Ostrowski Journal: J Cancer Date: 2020-01-01 Impact factor: 4.207